{"filings":[{"id":669196,"accession_number":"0001193125-26-239535","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-05-26T20:48:01+00:00","items":["5.07","9.01"],"status":"ready","headline":"Viking Therapeutics annual meeting elects two Class II directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["J. Matthew Singleton elected with 28.6M votes for; S. Kathryn Rouan with 22.0M for.","Ratification of CBIZ CPAs as independent auditor for FY 2026 approved (78.4M for, 1.2M against).","Advisory vote on named executive officer compensation passed (30.0M for, 12.8M against).","Quorum achieved with 80.1M shares (69.1% of outstanding) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94059,"accession_number":"0001193125-26-191487","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.","Initiation of Phase 3 trial for oral VK2735 expected in 4Q26; Phase 2 VENTURE-Oral showed up to 12.2% weight loss after 13 weeks.","Maintenance dosing study for VK2735 is ongoing with data expected in 3Q26; the study explores weekly, every-other-week, and monthly dosing.","IND filed for novel amylin agonist VK3019; Phase 1 trial initiation planned for 2Q26.","First quarter 2026 cash position was $603 million, with R&D expenses of $150.2 million and net loss of $158.3 million, compared to $45.6 million net loss in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106145,"accession_number":"0001193125-26-046536","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).","Cash & investments $706M at Dec 31, 2025 vs $903M a year earlier; burn reflects Phase 3 ramp.","VANQUISH-1 (obesity) enrollment completed >4,500 ahead of schedule; VANQUISH-2 (obesity+diabetes) near full.","Oral VK2735 to advance to Phase 3 in 3Q26 after FDA end-of-Phase 2 meeting; maintenance dosing data due 3Q26.","IND filing for novel amylin agonist planned in 1Q26; Phase 1 maintenance study fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122436,"accession_number":"0001193125-25-246775","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.","Cash, equivalents and short-term investments totaled $715M as of Sept 30, 2025, down from $903M at Dec 31, 2024.","Phase 3 VANQUISH-1 for VK2735 in obesity expects enrollment completion by end of 2025; VANQUISH-2 by Q1 2026.","Phase 2 VENTURE-Oral study showed up to 12.2% mean weight loss after 13 weeks; up to 97% achieved ≥5% weight loss.","Maintenance dosing study of VK2735 initiated; plans to file IND for dual amylin/calcitonin agonist in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139132,"accession_number":"0001607678-25-000003","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).","Up to 97% of VK2735 subjects achieved ≥5% weight loss vs 10% placebo; up to 80% achieved ≥10% vs 5% placebo.","Safety: 99% of GI-related TEAEs mild/moderate; discontinuation due to AE in 20% VK2735 vs 13% placebo.","Statistically significant weight loss seen in all doses >15 mg from Week 1 through Week 13.","Exploratory maintenance arm: weight loss sustained after down-titration from 90 mg to 30 mg daily for 7 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139131,"accession_number":"0000950170-25-097885","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.","Cash and investments $808M as of June 30, 2025, down from $903M at Dec 31, 2024.","Phase 3 VANQUISH program initiated: two placebo-controlled trials (obesity and obesity+type 2 diabetes) targeting ~5,600 patients.","Phase 2 VENTURE-Oral dosing trial enrollment completed (~280 patients); top-line results expected 2H25.","Amylin agonist program progressing; IND filing planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156661,"accession_number":"0000950170-25-077865","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.","Ratified CBIZ CPAs P.C. as independent auditor for FY2025: 75.2M for, 992K against, 473K abstentions.","Advisory say-on-pay proposal approved: 29.3M for, 14.5M against, 506K abstentions, 32.4M broker non-votes.","Meeting quorum of 76.7M shares (68.3% of 112.3M outstanding shares) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156660,"accession_number":"0000950170-25-057337","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.","Cash, cash equivalents & short-term investments totaled $852M at March 31, 2025, down from $903M at Dec 31, 2024.","Phase 3 trials for subcutaneous VK2735 in obesity expected to begin in 2Q25; Phase 2 VENTURE-Oral Dosing trial fully enrolled, data expected 2H25.","Signed broad manufacturing agreement with CordenPharma for VK2735 API and fill/finish capacity; prepayments from 2025-2028 credited against future orders.","Dual amylin/calcitonin receptor agonist (DACRA) program IND planned for 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156659,"accession_number":"0000950170-25-057323","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Viking Therapeutics appoints CBIZ as independent auditor after Marcum resignation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum resigned April 18, 2025, after CBIZ acquired its attest business.","Audit committee appointed CBIZ as auditor for FY2025 on April 22, 2025.","No disagreements or reportable events with Marcum in FY2023 or FY2024.","Company will file revised proxy for May 20, 2025 annual meeting to reflect CBIZ in Proposal 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175084,"accession_number":"0000950170-25-036820","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.","CordenPharma commits to multi-ton annual API supply; dedicated lines for 100M autoinjectors and 100M vial/syringe units.","Annual oral tablet capacity exceeds 1 billion units; capacities are expandable at Viking's option.","Phase 3 subcutaneous VK2735 trial planned to start Q2 2025; oral Phase 2 VENTURE trial ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175083,"accession_number":"0000950170-25-014464","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.","Cash, cash equivalents and short-term investments of $903M as of Dec 31, 2024, up from $362M a year earlier.","Initiation of Phase 3 studies for subcutaneous VK2735 in obesity planned for 2Q25 after FDA End-of-Phase 2 meeting.","Phase 2 VENTURE-Oral trial of VK2735 tablet underway in ~280 obese subjects; data expected 2H25.","Phase 2b VOYAGE in MASH: VK2809 showed MASH resolution rates up to 75% vs 29% placebo, and fibrosis improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192036,"accession_number":"0000950170-24-120267","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.","100% of subjects on 100 mg oral VK2735 reached ≥5% weight loss vs. 0% placebo; GI events mostly mild.","Phase 2 VENTURE: 94% of weight loss maintained 4 weeks post-final dose; supports once-monthly dosing.","78% of prediabetic patients on VK2735 shifted to normoglycemic over 13 weeks vs. 29% on placebo.","Oral Phase 2 to start by year-end 2024; injectable Phase 3 design to be discussed with FDA this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192035,"accession_number":"0000950170-24-116642","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.","Cash and equivalents of $930M at Sept 30, 2024, up from $362M at Dec 31, 2023.","End-of-Phase 2 meeting for subcutaneous VK2735 (obesity) planned for 4Q24; Phase 2 oral VK2735 trial expected to start 4Q24.","Positive Phase 2b VOYAGE results for VK2809 in NASH/MASH with fibrosis selected for oral presentation at AASLD Nov 19.","Positive Phase 1b results for VK0214 in X-ALD show reductions in very long-chain fatty acids and plasma lipids."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208511,"accession_number":"0000950170-24-086039","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.","Oral VK2735 Phase 2 trial in obesity expected to start in 4Q24; 28-day weight loss up to 5.3% from baseline.","VK2809 met secondary endpoints in NASH/fibrosis; NASH resolution rates 63-75% vs 29% placebo; End-of-Phase 2 meeting 4Q24.","Q2 net loss $22.3M ($0.20/share) vs $19.2M ($0.19) year ago; R&D expenses rose to $23.8M.","Cash and investments $942M at June 30, 2024, up from $362M at year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226203,"accession_number":"0000950170-24-068297","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).","Fibrosis improvement ≥1 stage with no NASH worsening: 44-57% for VK2809 vs 34% placebo (p<0.05 for 5 mg and 10 mg QOD, combined p=0.03).","Combined endpoint (NASH resolution + fibrosis improvement) achieved by 40-50% vs 20% placebo (p<0.05 for 5 mg, 10 mg QOD, combined p=0.003).","Liver fat reduction at 52 weeks: mean relative change -37% to -55%; ≥30% reduction in 64-88% of VK2809 patients (all p<0.0001 vs placebo).","GI adverse events similar to placebo; discontinuation rates low; LDL-C reductions of 20-25% vs placebo (p<0.01)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226202,"accession_number":"0000950170-24-063707","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.","2024 Equity Incentive Plan approved (48.5M for, 19.3M against).","2024 Employee Stock Purchase Plan approved (67.1M for, 0.7M against).","Advisory say-on-pay approved (63.2M for, 4.5M against).","Ratification of Marcum LLP as auditor for FY2024 approved (87.4M for, 0.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226201,"accession_number":"0000950170-24-047567","cik":1607678,"company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.","Phase 2 VENTURE: VK2735 hit primary endpoint; up to 14.7% weight loss from baseline, 13.1% placebo-adjusted at 13 weeks.","Phase 1 oral VK2735: up to 5.3% weight loss from baseline (3.3% placebo-adjusted) at 28 days; no SAEs; plan Phase 2 in obesity later 2024.","Phase 2b VOYAGE (VK2809 in NASH/fibrosis) 52-week histology data expected in 2Q24.","Q1 gross proceeds $632.5M from stock offering; cash & investments $963M as of Mar 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3297400000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}